array(40) {
  [0]=>
  string(4) "1871"
  ["article_id"]=>
  string(4) "1871"
  [1]=>
  string(37) "Haseeb Ahmad named new ABPI president"
  ["article_title"]=>
  string(37) "Haseeb Ahmad named new ABPI president"
  [2]=>
  string(120) "The Association of the British Pharmaceutical Industry (ABPI) has named Novartis' Haseeb Ahmad as its new president."
  ["short_description"]=>
  string(120) "The Association of the British Pharmaceutical Industry (ABPI) has named Novartis' Haseeb Ahmad as its new president."
  [3]=>
  string(120) "The Association of the British Pharmaceutical Industry (ABPI) has named Novartis' Haseeb Ahmad as its new president."
  ["description"]=>
  string(120) "The Association of the British Pharmaceutical Industry (ABPI) has named Novartis' Haseeb Ahmad as its new president."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "4"
  ["rss_id"]=>
  string(1) "4"
  [14]=>
  string(77) "http://www.pharmatimes.com/news/haseeb_ahmad_named_new_abpi_president_1286648"
  ["blog_url"]=>
  string(77) "http://www.pharmatimes.com/news/haseeb_ahmad_named_new_abpi_president_1286648"
  [15]=>
  string(19) "2019-05-03 17:31:46"
  ["add_date"]=>
  string(19) "2019-05-03 17:31:46"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:35:49"
  ["create_at"]=>
  string(19) "2019-05-09 16:35:49"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "1872"
  ["article_id"]=>
  string(4) "1872"
  [1]=>
  string(78) "Bayer joins Sensyne Health consortium for accelerating new medicine discovery "
  ["article_title"]=>
  string(78) "Bayer joins Sensyne Health consortium for accelerating new medicine discovery "
  [2]=>
  string(150) "Bayer is to become Sensyne Health’s preferred pharmaceutical partner to work together on the development of a national linked patient data capab"
  ["short_description"]=>
  string(150) "Bayer is to become Sensyne Health’s preferred pharmaceutical partner to work together on the development of a national linked patient data capab"
  [3]=>
  string(156) "Bayer is to become Sensyne Health’s preferred pharmaceutical partner to work together on the development of a national linked patient data capability."
  ["description"]=>
  string(156) "Bayer is to become Sensyne Health’s preferred pharmaceutical partner to work together on the development of a national linked patient data capability."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "4"
  ["rss_id"]=>
  string(1) "4"
  [14]=>
  string(117) "http://www.pharmatimes.com/news/bayer_joins_sensyne_health_consortium_for_accelerating_new_medicine_discovery_1286629"
  ["blog_url"]=>
  string(117) "http://www.pharmatimes.com/news/bayer_joins_sensyne_health_consortium_for_accelerating_new_medicine_discovery_1286629"
  [15]=>
  string(19) "2019-05-03 17:30:45"
  ["add_date"]=>
  string(19) "2019-05-03 17:30:45"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:35:49"
  ["create_at"]=>
  string(19) "2019-05-09 16:35:49"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "1873"
  ["article_id"]=>
  string(4) "1873"
  [1]=>
  string(79) "Successful digital health hub pilot shows promise as rolled out across England "
  ["article_title"]=>
  string(79) "Successful digital health hub pilot shows promise as rolled out across England "
  [2]=>
  string(150) "The digital health and wellbeing learning centre has become a trusted place where staff and volunteers can help people to improve their digital skills"
  ["short_description"]=>
  string(150) "The digital health and wellbeing learning centre has become a trusted place where staff and volunteers can help people to improve their digital skills"
  [3]=>
  string(151) "The digital health and wellbeing learning centre has become a trusted place where staff and volunteers can help people to improve their digital skills."
  ["description"]=>
  string(151) "The digital health and wellbeing learning centre has become a trusted place where staff and volunteers can help people to improve their digital skills."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "4"
  ["rss_id"]=>
  string(1) "4"
  [14]=>
  string(118) "http://www.pharmatimes.com/news/successful_digital_health_hub_pilot_shows_promise_as_rolled_out_across_england_1286628"
  ["blog_url"]=>
  string(118) "http://www.pharmatimes.com/news/successful_digital_health_hub_pilot_shows_promise_as_rolled_out_across_england_1286628"
  [15]=>
  string(19) "2019-05-03 17:28:49"
  ["add_date"]=>
  string(19) "2019-05-03 17:28:49"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:35:49"
  ["create_at"]=>
  string(19) "2019-05-09 16:35:49"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "2180"
  ["article_id"]=>
  string(4) "2180"
  [1]=>
  string(35) "ASCO/ASH update ESA recommendations"
  ["article_title"]=>
  string(35) "ASCO/ASH update ESA recommendations"
  [2]=>
  string(150) "The American Society of Clinical Oncology (ASCO) and the American Society of Hematology (ASH) have updated their recommendations on the management of "
  ["short_description"]=>
  string(150) "The American Society of Clinical Oncology (ASCO) and the American Society of Hematology (ASH) have updated their recommendations on the management of "
  [3]=>
  string(229) "
The American Society of Clinical Oncology (ASCO) and the American Society of Hematology (ASH) have updated their recommendations on the management of cancer-associated anaemia with erythropoiesis-stimulating agents (ESAs).
"
  ["description"]=>
  string(229) "
The American Society of Clinical Oncology (ASCO) and the American Society of Hematology (ASH) have updated their recommendations on the management of cancer-associated anaemia with erythropoiesis-stimulating agents (ESAs).
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "42"
  ["rss_id"]=>
  string(2) "42"
  [14]=>
  string(83) "http://www.gabionline.net//Biosimilars/Research/ASCO-ASH-update-ESA-recommendations"
  ["blog_url"]=>
  string(83) "http://www.gabionline.net//Biosimilars/Research/ASCO-ASH-update-ESA-recommendations"
  [15]=>
  string(19) "2019-05-03 17:04:19"
  ["add_date"]=>
  string(19) "2019-05-03 17:04:19"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:41:40"
  ["create_at"]=>
  string(19) "2019-05-09 16:41:40"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "2181"
  ["article_id"]=>
  string(4) "2181"
  [1]=>
  string(82) "WHO says more communication and education needed to increase access to biosimilars"
  ["article_title"]=>
  string(82) "WHO says more communication and education needed to increase access to biosimilars"
  [2]=>
  string(150) "The World Health Organization (WHO) has emphasized the importance of communication, trust and education in order to increase patient access to biosimi"
  ["short_description"]=>
  string(150) "The World Health Organization (WHO) has emphasized the importance of communication, trust and education in order to increase patient access to biosimi"
  [3]=>
  string(352) "
The World Health Organization (WHO) has emphasized the importance of communication, trust and education in order to increase patient access to biosimilars in high-income countries. The issues were discussed by Emer Cooke, Head of the Regulation of Medicines and other Health Technologies Department, at the 17th Biosimilars Medicines Conference.
"
  ["description"]=>
  string(352) "
The World Health Organization (WHO) has emphasized the importance of communication, trust and education in order to increase patient access to biosimilars in high-income countries. The issues were discussed by Emer Cooke, Head of the Regulation of Medicines and other Health Technologies Department, at the 17th Biosimilars Medicines Conference.
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "42"
  ["rss_id"]=>
  string(2) "42"
  [14]=>
  string(117) "http://www.gabionline.net//Reports/WHO-says-more-communication-and-education-needed-to-increase-access-to-biosimilars"
  ["blog_url"]=>
  string(117) "http://www.gabionline.net//Reports/WHO-says-more-communication-and-education-needed-to-increase-access-to-biosimilars"
  [15]=>
  string(19) "2019-05-03 16:50:33"
  ["add_date"]=>
  string(19) "2019-05-03 16:50:33"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:41:40"
  ["create_at"]=>
  string(19) "2019-05-09 16:41:40"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "2182"
  ["article_id"]=>
  string(4) "2182"
  [1]=>
  string(67) "Mixed beliefs about generics among patients in a Malaysian hospital"
  ["article_title"]=>
  string(67) "Mixed beliefs about generics among patients in a Malaysian hospital"
  [2]=>
  string(150) "The Malaysian Government is heavily subsidizing public healthcare expenditure in order to provide access to health care for all citizens. In 2017, tot"
  ["short_description"]=>
  string(150) "The Malaysian Government is heavily subsidizing public healthcare expenditure in order to provide access to health care for all citizens. In 2017, tot"
  [3]=>
  string(618) "
The Malaysian Government is heavily subsidizing public healthcare expenditure in order to provide access to health care for all citizens. In 2017, total healthcare expenditure in the country was approximately 9.4% of the annual budget. In order to overcome the increasing cost of health care, the government has implemented a National Generic Medicine Policy in 2006 to promote healthier competition in medicine pricing and to make medicines more affordable to the general public. After 10 years of policy implementation, authors from the Ministry of Health Malaysia assess patients' beliefs about generics.
"
  ["description"]=>
  string(618) "
The Malaysian Government is heavily subsidizing public healthcare expenditure in order to provide access to health care for all citizens. In 2017, total healthcare expenditure in the country was approximately 9.4% of the annual budget. In order to overcome the increasing cost of health care, the government has implemented a National Generic Medicine Policy in 2006 to promote healthier competition in medicine pricing and to make medicines more affordable to the general public. After 10 years of policy implementation, authors from the Ministry of Health Malaysia assess patients' beliefs about generics.
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "42"
  ["rss_id"]=>
  string(2) "42"
  [14]=>
  string(112) "http://www.gabionline.net//Generics/Research/Mixed-beliefs-about-generics-among-patients-in-a-Malaysian-hospital"
  ["blog_url"]=>
  string(112) "http://www.gabionline.net//Generics/Research/Mixed-beliefs-about-generics-among-patients-in-a-Malaysian-hospital"
  [15]=>
  string(19) "2019-05-03 16:39:17"
  ["add_date"]=>
  string(19) "2019-05-03 16:39:17"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:41:40"
  ["create_at"]=>
  string(19) "2019-05-09 16:41:40"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "2183"
  ["article_id"]=>
  string(4) "2183"
  [1]=>
  string(73) "Health Canada issues draft guidance on generics labelling and equivalence"
  ["article_title"]=>
  string(73) "Health Canada issues draft guidance on generics labelling and equivalence"
  [2]=>
  string(155) "Canada’s federal department responsible for health, Health Canada, has issued two new draft guidance documents for public consultation as part of th"
  ["short_description"]=>
  string(155) "Canada’s federal department responsible for health, Health Canada, has issued two new draft guidance documents for public consultation as part of th"
  [3]=>
  string(291) "
Canada’s federal department responsible for health, Health Canada, has issued two new draft guidance documents for public consultation as part of the agency’s effort to clarify the eligibility criteria for its abbreviated new drug submission (ANDS) pathway for generics.
"
  ["description"]=>
  string(291) "
Canada’s federal department responsible for health, Health Canada, has issued two new draft guidance documents for public consultation as part of the agency’s effort to clarify the eligibility criteria for its abbreviated new drug submission (ANDS) pathway for generics.
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "42"
  ["rss_id"]=>
  string(2) "42"
  [14]=>
  string(111) "http://www.gabionline.net//Guidelines/Health-Canada-issues-draft-guidance-on-generics-labelling-and-equivalence"
  ["blog_url"]=>
  string(111) "http://www.gabionline.net//Guidelines/Health-Canada-issues-draft-guidance-on-generics-labelling-and-equivalence"
  [15]=>
  string(19) "2019-05-03 16:18:39"
  ["add_date"]=>
  string(19) "2019-05-03 16:18:39"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:41:40"
  ["create_at"]=>
  string(19) "2019-05-09 16:41:40"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "1923"
  ["article_id"]=>
  string(4) "1923"
  [1]=>
  string(101) "FDA Approves Qternmet XR (dapagliflozin, saxagliptin and metformin hydrochloride) for Type 2 Diabetes"
  ["article_title"]=>
  string(101) "FDA Approves Qternmet XR (dapagliflozin, saxagliptin and metformin hydrochloride) for Type 2 Diabetes"
  [2]=>
  string(150) " 3 May 2019 -- The US Food and Drug Administration (FDA) has approved Qternmet XR (dapagliflozin, saxagliptin and metformin hydrochloride) extend"
  ["short_description"]=>
  string(150) " 3 May 2019 -- The US Food and Drug Administration (FDA) has approved Qternmet XR (dapagliflozin, saxagliptin and metformin hydrochloride) extend"
  [3]=>
  string(250) " 3 May 2019 -- The US Food and Drug Administration (FDA) has approved Qternmet XR (dapagliflozin, saxagliptin and metformin hydrochloride) extended release tablets as an oral adjunct treatment to diet and exercise to improve glycaemic control..."
  ["description"]=>
  string(250) " 3 May 2019 -- The US Food and Drug Administration (FDA) has approved Qternmet XR (dapagliflozin, saxagliptin and metformin hydrochloride) extended release tablets as an oral adjunct treatment to diet and exercise to improve glycaemic control..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "8"
  ["rss_id"]=>
  string(1) "8"
  [14]=>
  string(282) "https://www.drugs.com/newdrugs/fda-approves-qternmet-xr-dapagliflozin-saxagliptin-metformin-hydrochloride-type-2-diabetes-4959.html?utm_source=ddc&utm_medium=rss&utm_campaign=FDA+Approves+Qternmet+XR+%28dapagliflozin%2C+saxagliptin+and+metformin+hydrochloride%29+for+Type+2+Diabetes"
  ["blog_url"]=>
  string(282) "https://www.drugs.com/newdrugs/fda-approves-qternmet-xr-dapagliflozin-saxagliptin-metformin-hydrochloride-type-2-diabetes-4959.html?utm_source=ddc&utm_medium=rss&utm_campaign=FDA+Approves+Qternmet+XR+%28dapagliflozin%2C+saxagliptin+and+metformin+hydrochloride%29+for+Type+2+Diabetes"
  [15]=>
  string(19) "2019-05-03 15:05:03"
  ["add_date"]=>
  string(19) "2019-05-03 15:05:03"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:35:50"
  ["create_at"]=>
  string(19) "2019-05-09 16:35:50"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "2478"
  ["article_id"]=>
  string(4) "2478"
  [1]=>
  string(47) "Complete Response Letter from FDA for Barhemsys"
  ["article_title"]=>
  string(47) "Complete Response Letter from FDA for Barhemsys"
  [2]=>
  string(150) "Cambridge, UK and Indianapolis, US – 3 May 2019: Acacia Pharma Group plc (“Acacia Pharma”), a pharmaceutical company developing and "
  ["short_description"]=>
  string(150) "Cambridge, UK and Indianapolis, US – 3 May 2019: Acacia Pharma Group plc (“Acacia Pharma”), a pharmaceutical company developing and "
  [3]=>
  string(251) "Cambridge, UK and Indianapolis, US – 3 May 2019: Acacia Pharma Group plc (“Acacia Pharma”), a pharmaceutical company developing and commercialising hospital products for US and international markets, announces that it has received..."
  ["description"]=>
  string(251) "Cambridge, UK and Indianapolis, US – 3 May 2019: Acacia Pharma Group plc (“Acacia Pharma”), a pharmaceutical company developing and commercialising hospital products for US and international markets, announces that it has received..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "9"
  ["rss_id"]=>
  string(1) "9"
  [14]=>
  string(138) "https://www.drugs.com/nda/barhemsys_190503.html?utm_source=ddc&utm_medium=rss&utm_campaign=Complete+Response+Letter+from+FDA+for+Barhemsys"
  ["blog_url"]=>
  string(138) "https://www.drugs.com/nda/barhemsys_190503.html?utm_source=ddc&utm_medium=rss&utm_campaign=Complete+Response+Letter+from+FDA+for+Barhemsys"
  [15]=>
  string(19) "2019-05-03 08:05:27"
  ["add_date"]=>
  string(19) "2019-05-03 08:05:27"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-23 14:18:27"
  ["create_at"]=>
  string(19) "2019-05-23 14:18:27"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "1906"
  ["article_id"]=>
  string(4) "1906"
  [1]=>
  string(200) "Par Pharmaceutical, Inc. Issues Voluntary Nationwide Recall of One Lot of Mycophenolate Mofetil for Injection, USP Due to the Presence of a Glass Fragment Observed in One Vial of Reconstituted Product"
  ["article_title"]=>
  string(200) "Par Pharmaceutical, Inc. Issues Voluntary Nationwide Recall of One Lot of Mycophenolate Mofetil for Injection, USP Due to the Presence of a Glass Fragment Observed in One Vial of Reconstituted Product"
  [2]=>
  string(150) "Audience: Consumer, Health Professional, Pharmacy Endo International plc, announced today that one of its operating companies, Par Pharmaceutical, Inc"
  ["short_description"]=>
  string(150) "Audience: Consumer, Health Professional, Pharmacy Endo International plc, announced today that one of its operating companies, Par Pharmaceutical, Inc"
  [3]=>
  string(252) "Audience: Consumer, Health Professional, Pharmacy Endo International plc, announced today that one of its operating companies, Par Pharmaceutical, Inc., is voluntarily recalling one lot of Mycophenolate Mofetil for Injection, USP to the hospital and..."
  ["description"]=>
  string(252) "Audience: Consumer, Health Professional, Pharmacy Endo International plc, announced today that one of its operating companies, Par Pharmaceutical, Inc., is voluntarily recalling one lot of Mycophenolate Mofetil for Injection, USP to the hospital and..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "7"
  ["rss_id"]=>
  string(1) "7"
  [14]=>
  string(300) "https://www.drugs.com/fda/par-pharmaceutical-inc-issues-voluntary-nationwide-recall-one-lot-mycophenolate-mofetil-usp-due-14268.html?utm_source=ddc&utm_medium=rss&utm_campaign=Par+Pharmaceutical%2C+Inc.+Issues+Voluntary+Nationwide+Recall+of+One+Lot+of+Mycophenolate+Mofetil+for+Injection%2C+USP+Due+t"
  ["blog_url"]=>
  string(300) "https://www.drugs.com/fda/par-pharmaceutical-inc-issues-voluntary-nationwide-recall-one-lot-mycophenolate-mofetil-usp-due-14268.html?utm_source=ddc&utm_medium=rss&utm_campaign=Par+Pharmaceutical%2C+Inc.+Issues+Voluntary+Nationwide+Recall+of+One+Lot+of+Mycophenolate+Mofetil+for+Injection%2C+USP+Due+t"
  [15]=>
  string(19) "2019-05-03 08:00:00"
  ["add_date"]=>
  string(19) "2019-05-03 08:00:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:35:50"
  ["create_at"]=>
  string(19) "2019-05-09 16:35:50"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "1905"
  ["article_id"]=>
  string(4) "1905"
  [1]=>
  string(219) "Vivimed Life Sciences Pvt Ltd Issues Voluntary Nationwide Recall of Losartan Potassium 25 mg, 50 mg and 100 mg Tablets, USP Due to the Detection of Trace Amounts of N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) Impurity"
  ["article_title"]=>
  string(219) "Vivimed Life Sciences Pvt Ltd Issues Voluntary Nationwide Recall of Losartan Potassium 25 mg, 50 mg and 100 mg Tablets, USP Due to the Detection of Trace Amounts of N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) Impurity"
  [2]=>
  string(150) "Audience: Consumer, Health Professional, Pharmacy Vivimed Life Sciences Pvt Ltd (Vivimed) is recalling 19 lots of Losartan Potassium Tablets USP 25 mg"
  ["short_description"]=>
  string(150) "Audience: Consumer, Health Professional, Pharmacy Vivimed Life Sciences Pvt Ltd (Vivimed) is recalling 19 lots of Losartan Potassium Tablets USP 25 mg"
  [3]=>
  string(236) "Audience: Consumer, Health Professional, Pharmacy Vivimed Life Sciences Pvt Ltd (Vivimed) is recalling 19 lots of Losartan Potassium Tablets USP 25 mg, 50 mg, and 100 mg to consumer level. Due to the detection of an impurity –..."
  ["description"]=>
  string(236) "Audience: Consumer, Health Professional, Pharmacy Vivimed Life Sciences Pvt Ltd (Vivimed) is recalling 19 lots of Losartan Potassium Tablets USP 25 mg, 50 mg, and 100 mg to consumer level. Due to the detection of an impurity –..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "7"
  ["rss_id"]=>
  string(1) "7"
  [14]=>
  string(300) "https://www.drugs.com/fda/vivimed-sciences-pvt-ltd-issues-voluntary-nationwide-recall-losartan-potassium-25-mg-50-mg-100-mg-14269.html?utm_source=ddc&utm_medium=rss&utm_campaign=Vivimed+Life+Sciences+Pvt+Ltd+Issues+Voluntary+Nationwide+Recall+of+Losartan+Potassium+25+mg%2C+50+mg+and+100+mg+Tablets%2"
  ["blog_url"]=>
  string(300) "https://www.drugs.com/fda/vivimed-sciences-pvt-ltd-issues-voluntary-nationwide-recall-losartan-potassium-25-mg-50-mg-100-mg-14269.html?utm_source=ddc&utm_medium=rss&utm_campaign=Vivimed+Life+Sciences+Pvt+Ltd+Issues+Voluntary+Nationwide+Recall+of+Losartan+Potassium+25+mg%2C+50+mg+and+100+mg+Tablets%2"
  [15]=>
  string(19) "2019-05-03 08:00:00"
  ["add_date"]=>
  string(19) "2019-05-03 08:00:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:35:50"
  ["create_at"]=>
  string(19) "2019-05-09 16:35:50"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "2060"
  ["article_id"]=>
  string(4) "2060"
  [1]=>
  string(49) "Globus Medical Reports First Quarter 2019 Results"
  ["article_title"]=>
  string(49) "Globus Medical Reports First Quarter 2019 Results"
  [2]=>
  string(150) "AUDUBON, Pa., May  02, 2019  (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced its fi"
  ["short_description"]=>
  string(150) "AUDUBON, Pa., May  02, 2019  (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced its fi"
  [3]=>
  string(244) "
AUDUBON, Pa., May  02, 2019  (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced its financial results for the first quarter ended March 31, 2019.
"
  ["description"]=>
  string(244) "
AUDUBON, Pa., May  02, 2019  (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced its financial results for the first quarter ended March 31, 2019.
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "27"
  ["rss_id"]=>
  string(2) "27"
  [14]=>
  string(120) "http://www.globenewswire.com/news-release/2019/05/02/1815723/0/en/Globus-Medical-Reports-First-Quarter-2019-Results.html"
  ["blog_url"]=>
  string(120) "http://www.globenewswire.com/news-release/2019/05/02/1815723/0/en/Globus-Medical-Reports-First-Quarter-2019-Results.html"
  [15]=>
  string(19) "2019-05-03 04:15:00"
  ["add_date"]=>
  string(19) "2019-05-03 04:15:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:41:22"
  ["create_at"]=>
  string(19) "2019-05-09 16:41:22"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}